|
|
|
European Pharmaceutical Contractor
|
Back in 1996, when the original publisher of EPC invited me to become the Editor of the new magazine, I hardly anticipated the impact that the magazine would have. From a rather specialist publication it has developed into a broad ranging publication with editorial covering the whole waterfront of pharmaceutical development and beyond. In the 25 issues since, we have covered issues ranging from facts and figures about the CRO scene (perhaps my specialty), novel methods of drug discovery, electronic data capture, cutting-edge analytical techniques and literally hundreds more. Although the 'E' stands for European we have had special foci on Japan and other countries, including an article from Nelson Mandela, many articles from and about the US, as well as many looking at the developing industry in Eastern Europe and Scandinavia.
We have not neglected the vital areas of regulatory affairs or intellectual property, while we usually find room for an article on the commercial aspects of the pharmaceutical industry. It has sometimes been difficult to decide if an article is more suited to one of EPC's sister publications EBR or PMPS - but in the final analysis it has mattered little to our wide readership.
The publisher's staff have done much to make my job a pleasure, and much credit must go to the contributors themselves for keeping up such a high and lively standard. Nor must I forget the advertisers without whom EPC would not exist.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
6th European Forum for Qualified Person for Pharmacovigilance (QPPV)
24-26 April 2012, London, UK
This event is for European qualified persons for pharmacovigilance; deputy qualified persons; senior pharmacovigilance regulators and inspectors; CROs and consultants providing QPPV services; and national responsible persons for pharmacovigilance.
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
